# SEQUOIA (NCT02923921)

> Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: pegilodecakin
- Indication: second-line metastatic pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02923921
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Eli Lilly and Company
- Conditions: Pancreatic Cancer
- Interventions: Pegilodecakin; FOLFOX
- Enrollment: 567
- Primary outcome: Overall Survival

## Indexed commentary on SEQUOIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sequoia-nct02923921